Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report

A 55‐year‐old Chinese man with a right lung mass and lymph node metastasis (T4N3M0 IIIB) was diagnosed with lung adenocarcinoma after a CT‐guided biopsy. With the wide application of next‐generation sequencing (NGS) in tumour detection, we found a rare CCDC85A‐ALK fusion. The patient received alecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jieheng, Wang, Wenping, Lin, Jietao, Chen, Ruilian, Cao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575090/
https://www.ncbi.nlm.nih.gov/pubmed/36102237
http://dx.doi.org/10.1111/jcmm.17520
_version_ 1784811247627141120
author Lin, Jieheng
Wang, Wenping
Lin, Jietao
Chen, Ruilian
Cao, Yang
author_facet Lin, Jieheng
Wang, Wenping
Lin, Jietao
Chen, Ruilian
Cao, Yang
author_sort Lin, Jieheng
collection PubMed
description A 55‐year‐old Chinese man with a right lung mass and lymph node metastasis (T4N3M0 IIIB) was diagnosed with lung adenocarcinoma after a CT‐guided biopsy. With the wide application of next‐generation sequencing (NGS) in tumour detection, we found a rare CCDC85A‐ALK fusion. The patient received alectinib, which had marked efficacy. This is the first report of a lung adenocarcinoma patient harbouring a new uncommon anaplastic lymphocyte kinase fusion that showed a remarkable response to alectinib. NGS aids in selecting treatment in non‐small cell lung cancer patients.
format Online
Article
Text
id pubmed-9575090
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95750902022-10-17 Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report Lin, Jieheng Wang, Wenping Lin, Jietao Chen, Ruilian Cao, Yang J Cell Mol Med Short Communication A 55‐year‐old Chinese man with a right lung mass and lymph node metastasis (T4N3M0 IIIB) was diagnosed with lung adenocarcinoma after a CT‐guided biopsy. With the wide application of next‐generation sequencing (NGS) in tumour detection, we found a rare CCDC85A‐ALK fusion. The patient received alectinib, which had marked efficacy. This is the first report of a lung adenocarcinoma patient harbouring a new uncommon anaplastic lymphocyte kinase fusion that showed a remarkable response to alectinib. NGS aids in selecting treatment in non‐small cell lung cancer patients. John Wiley and Sons Inc. 2022-09-14 2022-10 /pmc/articles/PMC9575090/ /pubmed/36102237 http://dx.doi.org/10.1111/jcmm.17520 Text en © 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Lin, Jieheng
Wang, Wenping
Lin, Jietao
Chen, Ruilian
Cao, Yang
Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
title Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
title_full Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
title_fullStr Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
title_full_unstemmed Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
title_short Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
title_sort lung adenocarcinoma with an uncommon ccdc85a‐alk fusion responding to alectinib: a case report
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575090/
https://www.ncbi.nlm.nih.gov/pubmed/36102237
http://dx.doi.org/10.1111/jcmm.17520
work_keys_str_mv AT linjieheng lungadenocarcinomawithanuncommonccdc85aalkfusionrespondingtoalectinibacasereport
AT wangwenping lungadenocarcinomawithanuncommonccdc85aalkfusionrespondingtoalectinibacasereport
AT linjietao lungadenocarcinomawithanuncommonccdc85aalkfusionrespondingtoalectinibacasereport
AT chenruilian lungadenocarcinomawithanuncommonccdc85aalkfusionrespondingtoalectinibacasereport
AT caoyang lungadenocarcinomawithanuncommonccdc85aalkfusionrespondingtoalectinibacasereport

Ejemplares similares